PD‐1/PD‐L1 Blockade Therapy in Advanced Non‐Small‐Cell Lung Cancer: Current Status and Future Directions

• Published in: The oncologist (Dayton, Ohio) Vol. 24; no. S1; pp. S31 - S41
• Main Authors: Xia, Liliang, Liu, Yuanyong, Wang, Ying
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.02.2019
• Subjects: Antibodies, Monoclonal - immunology; Antibodies, Monoclonal - therapeutic use; B7-H1 Antigen - antagonists & inhibitors; B7-H1 Antigen - immunology; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - immunology; China; Clinical trials; Clinical Trials as Topic; Combination therapy; Humans; Immune checkpoint inhibitors; Immunotherapy - methods; Lung Cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - immunology; Non‐small‐cell lung cancer; PD‐1/PD‐L1; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Programmed Cell Death 1 Receptor - immunology; Randomized Controlled Trials as Topic; China; Clinical trials; Immune checkpoint inhibitors; PD‐1/PD‐L1; Combination therapy; Non‐small‐cell lung cancer

The use of immune checkpoint inhibitors (ICIs) has become one of the most promising approaches in the field of cancer therapy. Unlike the current therapies that target tumor cells, such as chemotherapy, radiotherapy, or targeted therapy, ICIs directly restore the exhausted host antitumor immune resp...